イヴォネシマブと化学療法によるEGFR変異の非小細胞肺がん: ランダム化臨床試験
, Wenfeng Fang1, Yuanyuan Zhao1
1Sun Yat-sen University Cancer Center, Guangzhou, China.
JAMA
|May 31, 2024
まとめ
イボネシマブと化学療法は,EGFRチロシンキナーゼ阻害剤 (EGFR- TKIs) で治療された非小細胞肺がん患者で,前進行性生存率を著しく改善しました. この組み合わせ治療は,再発または転移した疾患に対する新しい選択肢を提供して,許容可能な安全性プロファイルを示しました.
科学分野:
- 腫瘍学
- 医学 研究
- 臨床試験
背景:
- Epidermal成長因子受容体チロシンキナーゼ阻害剤 (EGFR- TKI) の治療で進行する非小細胞肺がん (NSCLC) 患者にとって最適な治療法は限られています.
- EGFR変異を持つ再発性または転移性NSCLCは,重要な臨床的課題であり,新しい治療戦略を必要とします.
研究 の 目的:
- イヴォネシマブと化学療法との併用による有効性と安全性を,再発性進行性または転移性NSCLCのEGFR変種を有する患者で,単独の化学療法と比較して評価する.
- イボネシマブと化学療法が,この患者集団における無進行生存率 (PFS) を改善するかどうかを判断する.
主な方法:
- 中国では55か所で二重盲検,プラセボ対照,ランダム化3期試験が行われました.
- 合計322人の適格な患者が登録され,アイボネシマブまたはプラセボ,ペメトレクセドおよびカルボプラチンとの併用,その後維持療法を受けるようにランダムに割り当てられました.
主要な成果:
- ivonescimab群では,中位進行性生存期 (PFS) がプラセボ群 (P < 0. 001) と比較して有意に長かった (7. 1ヶ月).
- 第3世代のEGFR- TKIで疾患が進行した患者や脳転移した患者を含むサブグループでPFSの利点が観察されました.
- プラセボ群 (35. 4%) よりも,イヴォネシマブ群で客観的な応答率が高かった.
- イヴォネシマブ群の3度またはそれ以上の治療に起因する有害事象は,プラセボ群 (49. 1%) と比較して,イヴォネシマブ群でより頻繁に発生し,そのほとんどは化学療法に関連していた.
結論:
- イボネシマブと化学療法は,TKIで治療されたNSCLC患者において,管理可能な安全性プロファイルでPFSの有意な改善を示した.
- この組み合わせ治療は,EGFR-TKI治療で進行した進行または転移性NSCLCの患者にとって有望な新しい治療法です.
さらに関連する動画
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
関連する概念動画
Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
